Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17683961 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL17684364 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL17684367 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL17683958 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL17684365 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL17683959 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL17684783 | 0.80 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL17684272 | 0.79 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7101907 | 0.79 | CHRM2 (0.40) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL4441548 | 0.79 | CHRM2 (0.40) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-3009421-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2016-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | SLC1A2, SLC6A5, SLC18A2 | SLC6A2 10/4885SLC6A4 12/4885SLC6A3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.